Neumora Therapeutics to Present at Leerink Global Healthcare Conference
Neumora Therapeutics (Nasdaq: NMRA), a clinical-stage biopharmaceutical company focused on brain disease treatments, has announced its upcoming presentation at the Leerink Global Healthcare Conference. The presentation is scheduled for Tuesday, March 11, 2025, at 10:00 a.m. ET in Miami, FL.
The company, which maintains a pipeline of seven clinical and pre-clinical brain disease programs, will make the presentation available via live webcast on their website's Events and Presentations section at www.neumoratx.com. The recording will remain accessible for up to 30 days following the event.
Neumora Therapeutics (Nasdaq: NMRA), un'azienda biofarmaceutica in fase clinica focalizzata sui trattamenti per le malattie cerebrali, ha annunciato la sua prossima presentazione alla Leerink Global Healthcare Conference. La presentazione è programmata per martedì 11 marzo 2025, alle 10:00 ET a Miami, FL.
L'azienda, che mantiene un portafoglio di sette programmi clinici e pre-clinici per malattie cerebrali, renderà disponibile la presentazione tramite webcast dal vivo nella sezione Eventi e Presentazioni del loro sito web all'indirizzo www.neumoratx.com. La registrazione rimarrà accessibile per un massimo di 30 giorni dopo l'evento.
Neumora Therapeutics (Nasdaq: NMRA), una empresa biofarmacéutica en etapa clínica centrada en tratamientos para enfermedades cerebrales, ha anunciado su próxima presentación en la Leerink Global Healthcare Conference. La presentación está programada para el martes 11 de marzo de 2025, a las 10:00 a.m. ET en Miami, FL.
La empresa, que mantiene un portafolio de siete programas clínicos y preclínicos para enfermedades cerebrales, hará disponible la presentación a través de una transmisión en vivo en la sección de Eventos y Presentaciones de su sitio web en www.neumoratx.com. La grabación permanecerá accesible durante un máximo de 30 días después del evento.
Neumora Therapeutics (Nasdaq: NMRA)는 뇌 질환 치료에 중점을 둔 임상 단계의 생명공학 회사로, Leerink Global Healthcare Conference에서의 발표를 발표했습니다. 발표는 2025년 3월 11일 화요일 오전 10시 ET에 플로리다주 마이애미에서 예정되어 있습니다.
회사는 7개의 임상 및 전임상 뇌 질환 프로그램을 보유하고 있으며, 발표는 www.neumoratx.com의 이벤트 및 발표 섹션에서 라이브 웹캐스트를 통해 제공될 예정입니다. 녹화는 이벤트 후 최대 30일 동안 접근 가능합니다.
Neumora Therapeutics (Nasdaq: NMRA), une entreprise biopharmaceutique en phase clinique axée sur les traitements des maladies cérébrales, a annoncé sa prochaine présentation lors de la Leerink Global Healthcare Conference. La présentation est prévue pour le mardi 11 mars 2025, à 10h00 ET à Miami, FL.
L'entreprise, qui dispose d'un portefeuille de sept programmes cliniques et précliniques pour les maladies cérébrales, mettra la présentation à disposition via un webinaire en direct dans la section Événements et Présentations de son site web à l'adresse www.neumoratx.com. L'enregistrement restera accessible pendant 30 jours après l'événement.
Neumora Therapeutics (Nasdaq: NMRA), ein biopharmazeutisches Unternehmen in klinischer Phase, das sich auf Behandlungen für Gehirnerkrankungen konzentriert, hat seine bevorstehende Präsentation auf der Leerink Global Healthcare Conference angekündigt. Die Präsentation ist für Dienstag, den 11. März 2025, um 10:00 Uhr ET in Miami, FL, geplant.
Das Unternehmen, das über ein Portfolio von sieben klinischen und präklinischen Programmen für Gehirnerkrankungen verfügt, wird die Präsentation über einen Live-Webcast in der Rubrik Veranstaltungen und Präsentationen auf seiner Website www.neumoratx.com zur Verfügung stellen. Die Aufzeichnung wird bis zu 30 Tage nach der Veranstaltung zugänglich sein.
- None.
- None.
WATERTOWN, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical and pre-clinical brain disease programs, today announced that the Company will present at the Leerink Global Healthcare Conference being held in Miami, FL on Tuesday, March 11, 2025 at 10:00 a.m. ET.
A live webcast of the presentation will be available on the Events and Presentations section of the Company’s website at www.neumoratx.com. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days.
About Neumora
Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. Our therapeutic pipeline currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Our work is supported by an integrated suite of translational, clinical, and computational tools to generate insights that can enable precision medicine approaches. Neumora’s mission is to redefine neuroscience drug development by bringing forward the next generation of novel therapies that offer improved treatment outcomes and quality of life for patients suffering from brain diseases.
Neumora Contact:
Helen Rubinstein
315-382-3979
Helen.Rubinstein@neumoratx.com
FAQ
When is Neumora Therapeutics (NMRA) presenting at the Leerink Global Healthcare Conference 2025?
How many clinical and pre-clinical programs does NMRA currently have in its pipeline?
How long will NMRA's Leerink Conference presentation recording be available?
Where can investors watch Neumora's (NMRA) Leerink Conference presentation?
